AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence

Pembro plus gemcitabine and cisplatin potential option for metastatic or unresectable biliary tract cancer

Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC

Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival

Atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk HCC

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients

IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours

Higher BMI may be linked with worse survival among SBS88 positive CRC patients

MatchMiner: An open-source AI precision medicine trial matching platform

Test identifies tumour-infiltrating cell densities as prognostic biomarkers across a pan-cancer cohort